AUTL Maintained at Buy by H.C. Wainwright, May 2026

H.C. Wainwright maintained its Buy rating on Autolus Therapeutics (AUTL) while raising the price target to $10 from $9 on May 14, 2026. The analyst firm’s AUTL maintained rating reflects confidence in the clinical-stage biopharmaceutical company’s T cell therapy pipeline. AUTL trades at $1.59 with a market cap of $423 million. The stock has faced headwinds, down 7% today but up 30% over the past year. Meyka AI rates AUTL with a grade of B, suggesting a hold position. This AUTL maintained rating comes as the company advances multiple cancer immunotherapy programs through clinical trials.

H.C. Wainwright’s AUTL Maintained Rating and Price Target Increase

Price Target Raised to $10

H.C. Wainwright raised its price target on AUTL maintained rating to $10 per share, up from the previous $9 target. This represents upside of 528% from the current trading price of $1.59. The analyst firm kept its Buy rating intact, signaling continued belief in the company’s long-term potential. The price target increase reflects confidence in Autolus’ clinical pipeline. The AUTL maintained rating demonstrates the analyst’s view that near-term volatility does not diminish the company’s strategic value.

Analyst Consensus Remains Bullish

Across the Street, three analysts rate AUTL as Buy, with no Hold or Sell ratings. This unanimous bullish stance contrasts sharply with the stock’s recent trading weakness. The consensus rating of 4.0 (on a scale where 5 is Strong Buy) shows strong institutional support. Despite the AUTL maintained rating, the stock has declined 7% today and 20% year-to-date. Analyst conviction remains high despite market skepticism about clinical-stage biotech valuations.

Autolus Therapeutics Pipeline and Clinical Progress

T Cell Therapy Programs in Development

Autolus develops programmed T cell therapies targeting multiple cancer types. The lead program, AUTO1, targets CD19 in adult acute lymphoblastic leukemia and is in Phase 1b/2 trials. AUTO1/22 addresses pediatric ALL in Phase 1 testing. AUTO4 targets TRBC1 in peripheral T cell lymphoma. AUTO6NG and AUTO8 address neuroblastoma and multiple myeloma respectively. The company’s clinical-stage focus means revenue remains minimal at $0.28 per share trailing twelve months. Yet the AUTL maintained rating reflects belief these programs can reach commercialization.

Financial Position and Cash Runway

Autolus holds $1.13 per share in cash, providing runway for clinical development. The company reported a current ratio of 5.94, indicating strong liquidity. However, net losses reached $1.08 per share trailing twelve months. Operating cash flow was negative $1.07 per share. The company’s debt-to-equity ratio stands at 1.97, reflecting moderate leverage. Despite unprofitability, the AUTL maintained rating acknowledges the company’s ability to fund operations through clinical milestones.

Meyka AI Grade and Technical Outlook

Meyka AI Rates AUTL with Grade B

Meyka AI rates AUTL with a grade of B, suggesting a Hold position. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 66.87 out of 100 reflects mixed fundamentals. Strong liquidity and analyst support offset concerns about negative earnings and cash burn. These grades are not guaranteed and we are not financial advisors.

Technical Signals Show Mixed Momentum

The RSI stands at 53.06, indicating neutral momentum without overbought or oversold conditions. The MACD shows minimal bullish divergence with a histogram of 0.01. Stochastic indicators at 67.59 suggest mild overbought conditions. The stock trades within Bollinger Bands with the middle band at $1.55. Volume surged to 2.99 million shares, 83% above average. Technical weakness contradicts the AUTL maintained rating, suggesting near-term consolidation before potential recovery.

Stock Performance and Valuation Metrics

Recent Price Action and Volatility

AUTL trades at $1.59, down from the $1.71 previous close. The 52-week range spans $1.18 to $2.70, showing significant volatility. Year-to-date performance is negative 20.1%, yet the stock gained 30.3% over the past twelve months. The 50-day moving average sits at $1.49, while the 200-day average is $1.57. Today’s 7% decline reflects broader biotech sector weakness. Despite the AUTL maintained rating, short-term technicals remain challenged.

Valuation Relative to Peers

The price-to-sales ratio of 5.53 appears elevated for a pre-revenue biotech. The price-to-book ratio of 2.34 reflects market skepticism about asset quality. The enterprise value-to-sales multiple of 8.81 suggests the market prices in significant execution risk. However, the AUTL maintained rating from H.C. Wainwright implies these metrics undervalue the pipeline’s potential. Biotech valuations typically compress until clinical success de-risks the investment thesis.

Final Thoughts

H.C. Wainwright raised its $10 price target on Autolus Therapeutics, reflecting confidence in the company’s T cell therapy platform despite near-term weakness. Strong cash reserves and advancing clinical programs support the bullish view, though negative earnings and cash burn remain concerns. The Hold consensus across analysts suggests caution for most investors. Stock recovery depends on positive Phase 1b/2 data for AUTO1 and pipeline advancement. Investors should monitor clinical updates and cash runway closely before committing capital.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.